Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMX-049 multiple-dose pharmacology in subjects with normal or impaired renal function
jRCT2080224863Phase 2Completed
- Sponsor
- Teijin Pharma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TMX-049 in hyperuricemia and chronic kidney disease (CKD) (3 arms), sponsored by Teijin Pharma. Primary endpoints: Pharmacokinetics of TMX-049, Pharmacodynamics - serum uric acid change and 1 more. Started Sep 2019; status: completed.
02
Drugs
TMX-049
03
Conditions
hyperuricemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080224863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224863.